Individualized Homoeopathy Added to Standard Pharmacological Care for Migraine: A Pragmatic Randomized Open-Label Blinded-Endpoint Controlled Trial.
Shilpa Prasad, E Ratnasabapathy, Hariram Venkatesan et al.
✦ AI-curated · Sources linked
In 30 seconds
This pragmatic, two-arm randomized open-label, blinded-endpoint trial compared individualized homoeopathy added to standard pharmacological care with standard care alone in 120 adults with migraine and substantial baseline HIT-6 scores. At 6 months, the adjunctive-care group had greater reductions in headache impact and monthly migraine days: HIT-6 fell by 16.8 versus 9.1 points, and monthly migraine days by 9.1 versus 4.8 days. The authors interpret the findings as improvement associated with the combined adjunctive care package, not evidence isolating the effect of specific remedies.
Key findings
- HIT-6 reduction at 6 months was 16.8 versus 9.1 points; the baseline-adjusted difference was 7.86 (95% CI 5.59-10.12; p < 0.001).
- Monthly migraine days fell by 9.1 versus 4.8 days; the adjusted difference was 3.64 (95% CI 3.02-4.26; p < 0.001).
- A ≥6-point HIT-6 reduction occurred in 98.3% versus 66.7%; 80.0% versus 28.3% reported being much or very much improved.
- Any adverse event occurred in 23.3% versus 33.3%, with no statistically clear between-group difference demonstrated.
Why it matters
Daily functioning and headache burden are important outcomes in migraine care. The trial reports improvements in both HIT-6 and monthly migraine days when individualized homoeopathy was added to standard care, alongside concordant medication-use findings. However, the open-label design and additional clinician contact mean the results reflect the whole adjunctive-care package; they do not establish the specific effect of homoeopathic remedies.
What to keep in mind
The open-label design and additional clinician contact prevent attribution of the observed differences to specific remedies alone. The sample size does not establish broad safety.